Overview
NICE is unable to recommend the use in the NHS of loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder because no evidence submission was received from the manufacturer of the technology.
Last reviewed: 22 May 2013
Next review: We will review this decision if the company decides to make a submission.